ILIrina B. Lysenko

Irina B. Lysenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irina B. Lysenko has a total of 311 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Shifts in subpopulations and immunophenotypic subsets of normal blood lymphocytes in the patients with chronic lymphocytic leukemia during immunochemotherapy

    by O. N. Selyutina, N. K. Guskova, E. Yu. Zlatnik, I. B. Lysenko, E. A. Dzhenkova, L. Yu. Vladimirova, О. Н. Селютина, Н. К. Гуськова, Е. Ю. Златник, И. Б. Лысенко, et al.

    Immunological changes in normal lymphocytes subpopulations in blood of patients with chronic lymphocytic leukemia (CLL) may play a negative role in the disease progression. The aim of our study was to evaluate the effect of immunochemotherapy on the subpopulation composition and immunophenotypic features of normal lymphocytes in blood of CLL patients. Patients and methods: The study included 37 men, 25 women with CLL at Binet stages B, C, median age 64 (50-71) years old. The patients received 6 cycles of immunochemotherapy: RB (Rituximab + Bendamustine), or FCR (Fludarabine + Cyclophosphamide + Rituximab). The subpopulation profile of polyclonal B cells, T lymphocytes (T helpers, T-regulatory cells, T cytotoxic cells), NK lymphocytes, as well as expression of PD1, PD-L1, LAG3 were studied in blood samples of patients before and after treatment. The studies were performed using flow cytometry technique (Navios 10/3, Beckman Coulter, USA). Statistical analysis is performed in Statistica 13.0. Results: The study showed that all patients with CLL had significant quantitative and functional changes in the subpopulation profiles of B, T, and NK lymphocytes before and after therapy. The proportion of normal polyclonal B cells among all lymphocytes before treatment was reduced being characterized by PD1 expression. The therapy leads to partial restoration of the normal B cell population, which did not show expression of PD1, PD-L1, LAG3. Before and after treatment, CD4+ and CD8+T cells showed the highest expression of PD1, thus suggesting alterations of their antitumor functions. After treatment, the T lymphocyte microenvironment tends to recover due to an increase in their number. However, persistence of PD1 expression on T cells apparently prevents the complete restoration of their functional activity. Moreover, an increased content of T-regulatory cells, and maintenance of PD1 and LAG3 expression on NK lymphocytes may promote suppression of antitumor immune response and reduce the probability of long-term remission. In this regard, monitoring of immunological parameters during therapy is useful for assessing the degree of immune response dysregulation and, thus, timely planning of antitumor treatment and corrective immunotherapy.

  • Open Access

    Obinutuzumab-Based Regimens in the First-Line Therapy for Follicular Lymphoma: Data from Real-World Clinical Practice in 41 Medical Institutions

    by Lali Galimovna Babicheva, G. S. Tumyan, I. V. Poddubnaya, G. V. Anisimova, O. Yu. Arzhanukhina, E. N. Babich, Yu. M. Bala, V. I. Bakhtina, O. V. Berezina, I. A. Bogomolova, et al.

    AIM. To assess the efficacy and safety of combined obinutuzumab-based regimens in the first-line therapy for follicular lymphoma (FL) in real-world clinical practice. MATERIALS & METHODS. This retrospective multicenter study enrolled 279 newly diagnosed FL patients treated with obinutuzumab in combination with chemotherapy at 41 medical institutions in Russia from 2018 to 2026. The median age of patients was 49.2 years (range 30–83 years), 60.6 % of them were women. Obinutuzumab-based regimens were predominantly administered to patients with stage III/IV (86.4 %), advanced tumor spread (60.2 %), and often with intraabdominal location (76.3 %). More than 1/3 of patients had extranodal lesions (41.9 %) and bulky tumors (34.8 %). According to FLIPI score, there were 74.9 % of patients with intermediate and poor prognosis. More than half of the patients (54.4 %) received anthracycline-based G-CHOP regimen as initial therapy, GB was administered to 30.1 % of patients. Maintenance therapy with obinutuzumab was used in 72.8 % of cases. RESULTS. Overall response to therapy was achieved in 95.6 % of patients, the rate of complete metabolic response was 91.1 %. Adverse events of any grade were observed in 51.8 % of patients, grade ≥ 3 was identified in 29 % (primarily neutropenia and infectious complications). With the median follow-up of 16.3 months, disease progression or relapse were diagnosed in 21 (7.5 %) patients, histological transformation into diffuse large B-cell lymphoma was reported after 6 out of 14 biopsies performed at the stage of FL relapse. The 2-year progression-free survival was 89.6 %, and the 2-year overall survival was 98 %. CONCLUSION. The results of this study confirm high efficacy of obinutuzumab in the first-line therapy for FL patients with prognostically unfavorable characteristics of tumor. Overall and complete metabolic response rates are consistent with the international data. The administration of obinutuzumab-based regimens provide significant therapeutic control of the disease and confirm the reproducibility of the data from clinical studies in real-world healthcare practice.

  • Open Access

    Antitumor and Antimetastatic Activity of a Novel Pyrimidin-4-one Derivative in the B16–F10 Melanoma Mouse Model: A Pilot Study

    by Олег Иванович Кит, Елена Михайловна Франциянц, Полина Сергеевна Качесова, Алла Ивановна Шихлярова, Эдуард Константинович Алексеев, Иван Панайотович Кодониди, Александр Алексеевич Глушко, Лидия Константивна Трепитаки, Алексей Сергеевич Чиряпкин, Виталий Игоревич Вошедский, et al.

    Введение. Меланома кожи характеризуется высоким метастатическим потенциалом. Участие EGFR в инвазии и прогрессировании меланомы обосновывает поиск новых EGFR-ориентированных антиметастатических подходов. Цель. Оценка влияния нового производного пиримидин-4-она (6MPSVan-Na) на рост, метастазирование и морфологию перевивной меланомы В16-F10. Материалы и методы. Эксперимент выполнен на самцах мышей C57BL/6 с подкожно трансплантированной меланомой В16–F10. Животные были распределены на три группы (по n = 10 в каждой): основная группа (6MPSVan-Na, 18,7 мг/кг внутримышечно); отрицательный контроль (вода для инъекций внутримышечно); группа гефитиниба (43,4 мг/кг перорально) как позитивный контроль чувствительности модели к ингибиторам тирозинкиназы EGFR. Воздействие проводили в течение пяти дней со дня перевивки, через два дня курс повторяли. Оценивали латентный период, динамику объема и торможения роста опухоли (ТРО %), продолжительность жизни, выживаемость (Kаплан — Майер), частоту макрометастазов. Проведен гистологический анализ опухолевой ткани. Статистическая обработка: критерии Манна — Уитни, точный критерий Фишера, log-rank-тест, ANOVA (уровень значимости α = 0,05). Результаты. Исследование выявило чувствительность меланомы В16-F10 к действию референтного препарат гефитиниба. Профиль противоопухолевой активности экспериментального соединения 6MPSVan-Na характеризовался торможением роста меланомы в постэкспозиционный период (ТРО % ≥ 50 %), статистически значимым увеличением продолжительности жизни мышей, снижением частоты выявления макрометастазов в легких до 20 %, в лимфоузлах — до 30 % (p < 0,05). После воздействия 6MPSVan-Na преимущественно определялись морфологические признаки некроптоза (обширный некроз, выраженная инфильтрация лимфоцитами и гистиоцитами, формирование лимфоцитарного вала и соединительнотканной капсулы). Заключение. В пилотном исследовании новое производное пиримидин-4-она продемонстрировало противоопухолевую и антиметастатическую активность в отношении меланомы В16-F10, реализующуюся, вероятно, через активацию некроптоза и стимуляцию опухолеспецифического иммунного ответа. Полученные данные обосновывают дальнейшее изучение 6MPSVan-Na в качестве потенциального антиметастатического агента при меланоме.

  • Open Access

    Combination of stereotactic radiotherapy and intra-arterial chemoembolization in the treatment of a patient with unresectable pancreatic cancer

    by O. I. Kit, V. I. Voshedskii, P. G. Sakun, E. N. Kolesnikov, G. Yu. Egorov, E. A. Dzhenkova, L. Ya. Rozenko, S. G. Vlasov, M. A. Komandirov, E. A. Kashchaeva, et al.

    Pancreatic cancer (PC) is one of the most aggressive malignancies. The 5-year overall survival rate for this disease is only approximately 6%, with a median survival of 13.6 months. Despite advances in surgical approaches and systemic therapy, the 5-year survival rate continues to decline. Currently, complete cure can only be achieved through radical surgical resection of the tumor at an early stage of the disease. Involvement of critical abdominal structures significantly complicates surgical intervention. In such cases, neoadjuvant therapy may increase the likelihood of achieving an R0 resection. In terms of the type of radiation used in the preoperative setting, stereotactic body radiation therapy (SBRT) is an alternative to conventional fractionated radiation therapy. It offers greater convenience by minimizing prolonged interruptions in systemic therapy and has a favorable toxicity profile. This article presents a clinical case describing the patient's course from the outpatient stage of medical care through follow-up examination after completion of multimodal treatment. A clinical case demonstrating the effective use of stereotactic radiotherapy in combination with intra-arterial chemoembolization as part of the comprehensive treatment of a patient with locally advanced PC is presented. The report is of particular interest to oncologists and radiation oncologists, as it demonstrates the high efficacy of multimodal therapy for locally advanced PC.

  • Open Access

    Acute toxicity of the indole alkaloid corinan and the novel synthetic compound curcumoberberine with antitumor activity compared with the isoquinoline alkaloid berberine

    by E. Yu. Zlatnik, Ya. S. Enin, E. M. Nepomnyashchaya, N. S. Bendersky, O. N. Burov, Yu. V. Dzigunova, A. N. Dryapak, V. I. Rumu, V. B. Lysenko, Е. Ю. Златник, et al.

    Acute toxicity of the indole alkaloid corinan and the novel synthetic compound curcumoberberine with antitumor activity compared with the isoquinoline alkaloid berberine | Zlatnik | South Russian Journal of Cancer Острая токсичность индольного алкалоида коринана и нового синтезированного соединения куркумоберберина, проявляющих противоопухолевую активность, в сравнении с изохинолиновым алкалоидом берберином | Златник | Южно-Российский онкологический журнал/ South Russian Journal of Cancer

  • Open Access

    Pola-R-CHP Regimen as First-Line Therapy for Diffuse Large B-Cell Lymphoma: A Retrospective Study of Real-World Clinical Practice

    by Anastasiya Aleksandrovna Semenova, G. S. Tumyan, Yu. V. Ermakova, A. S. Chuprakova, A. P. Chernova, M. V. Frolova, N. B. Mikhailova, L. V. Fedorova, O. D. Serdyuk, S. V. Samarina, et al.

    BACKGROUND. For more than 20 years, the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) has been the R-CHOP regimen. However, about 30–40 % of patients experience relapsed/refractory disease. In the randomized POLARIX study, polatuzumab vedotin-based regimen (Pola-R-CHP) demonstrated a significant progression-free survival advantage over the standard R-CHOP. Yet, the evidence on the use of Pola-R-CHP in the real-world clinical practice in the Russian Federation is currently missing. AIM. To assess the efficacy and safety of the Pola-R-CHP regimen in patients with newly diagnosed DLBCL in a real-world setting in the Russian Federation. MATERIALS & METHODS. The multi-center retrospective study enrolled the data from 84 patients (48 men and 36 women) with immunomorphologically verified DLBCL diagnosis treated with polatuzumab vedotin-based first line therapy at 30 medical institutions of the Russian Federation in the period of 2022–2026. The median age of patients was 63 years (range 22–87 years). In 88 % of patients, DLBCL grade 3–4 was reported, 86 % belonged to a high-risk (IPI ≥ 3) group. The primary endpoint was complete response (CR) and overall response (OR) rate after 6 therapy cycles. Secondary endpoints included overall survival (OS), progression-free survival (PFS), metabolic response reported by PET/CT, and the analysis of safety profile. RESULTS. Full treatment was completed by 68 (81 %) out of 84 patients. After treatment, CR was 80.9 % and OR was 95.0 %. By PET/CT, complete metabolic response was achieved in 47/60 (78 %) patients. The median follow-up was 15.5 months. Neither median PFS nor median OS were achieved; the 2-year PFS was 82.5 % and the 2-year OS was 85.0 %. Most common adverse events (AEs) of any grade were neutropenia (67 %), leukopenia (55 %), anemia (35 %), and febrile neutropenia (14 %). AEs ≥ grade 3 were reported in 31 % of patients. CONCLUSION. In the real-world clinical practice in the Russian Federation, the Pola-R-CHP regimen showed high efficacy and favorable safety profile in the first-line therapy for DLBCL, also in the population of high-progression-risk patients. The results of the study are consistent with international data and prove the feasibility of risk-adapted treatment for DLBCL.

  • Open Access

    Gastroenterostomy in non-Hodgkin B-cell lymphoma complicated by decompensated gastric outlet obstruction

    by M. S. Kazanchyan, Ya. S. Gaysultanova, N. V. Nikolaeva, A. V. Snezhko, I. B. Lysenko, L. Yu. Vladimirova, D. S. Petrov, Yu. A. Fomenko, E. N. Kolesnikov, Я. С. Гайсултанова

    Primary gastric non- Hodgkin lymphomas represent the most common extranodal localization of lymphoproliferative disorders. The current standard of care, first-line immunochemotherapy based on rituximab (R-CHOP and CHOP-like reg imens), demonstrates high efficacy, achieving complete response in the majority of patients. However, 8–25 % of patients develop local life-threatening complications during or after treatment, among which gastric outlet obstruction (pyloric stenosis) is the most common. In routine clinical practice, elective surgical intervention is generally not performed in patients with lymphomas because these tumors are highly sensitive to systemic drug therapy. This article presents a clinical case of a 49-year-old patient with stage IV extranodal B-cell gastric lymphoma and HIV-positive status, demonstrating the role of palliative surgical intervention. Despite achieving a partial metabolic response to polychemotherapy (EPOCH/R-CHOP regimens), the patient developed decompensated cicatricial- tumorous pyloric stenosis. This complication required active surgical management. Gastrojejunostomy was successfully performed as a palliative procedure, creating a bypass for gastric emptying into the jejunum while circumventing the obstruction site, which significantly improved the patient's quality of life. The postoperative course was uneventful, and no signs of progression of the underlying lymphoproliferative disease were observed during long-term follow-up. An additional advantage of the selected surgical approach was the rapid restoration of the patient's nutritional status while preserving oral feeding. The presented clinical case confirms the feasibility of an individualized approach to the selection of palliative treatment strategies in patients with complicated gastric lymphoma.

  • Open Access

    ВЛИЯНИЕ БЕРБЕРИНА НА ФУНКЦИОНАЛЬНЫЕ СВОЙСТВА МОНОНУКЛЕАРНЫХ КЛЕТОК ПЕРИФЕРИЧЕСКОЙ КРОВИ У ПАЦИЕНТОВ С ДИФФУЗНОЙ В-КЛЕТОЧНОЙ КРУПНОКЛЕТОЧНОЙ ЛИМФОМОЙ С РАЗЛИЧНЫМ ОТВЕТОМ НА ТЕРАПИЮ

    by М.с. Казанчян, А.б. Сагакянц, И.б. Лысенко, С.ю. Филиппова, Е.с. Бондаренко, И.в. Межевова, Е.ю. Златник, Я.с. Гайсултанова

    Изучение функционального состояния иммунокомпетентных клеток представляет интерес для поиска дополнительных предикторов ответа на лечение. Цель исследования – провести сравнительную оценку исходного иммунного статуса и функциональной активности мононуклеарных клеток периферической крови при воздействии берберина in vitro у пациентов с противоположным клиническим ответом на терапию (полный метаболический ответ и раннее прогрессирование с летальным исходом). В исследование включены два клинических случая впервые диагностированной лимфомы II стадии с сопоставимыми прогностическими характеристиками и различным исходом лечения. Иммунофенотипирование лейкоцитов периферической крови проводили методом проточной цитометрии с оценкой результатов на BD FACSCanto. Функциональную активность мононуклеарных клеток периферической крови оценивали in vitro методом колониеобразования при воздействии берберина в концентрациях 1, 2 и 4 мкМ в условиях базальной и митогенной (фитогемагглютинин 4 мкг/мл) стимуляции. Количественный анализ колоний выполняли с использованием автоматического клеточного анализатора Lionheart FX. Выявлены различия в субпопуляционном составе лимфоцитов и пролиферативном ответе клеток. Берберин оказывал дозозависимое стимулирующее влияние на колониеобразование, при этом пик ответа различался в зависимости от клинического исхода. Полученные данные свидетельствуют о возможной связи функционального состояния мононуклеарных клеток и их чувствительности к берберину с клиническим ответом при диффузной В-клеточной крупноклеточной лимфоме. Выявленные тенденции обосновывают целесообразность дальнейших исследований берберина как потенциального иммуномодулирующего агента.

  • Open Access

    A Rare Case Report of the В-Cell Chronic Lymphocytic Leukemia Diagnosis During the Stage of Transformation into Diffuse Large B-cell Lymphoma (Richter Syndrome)

    by N. K. Guskova, Olesya Nikolaevna Selyutina, I. B. Lysenko, E. M. Nepomnyashchaya, E. A. Dzhenkova, I. A. Novikova, M. S. Nekrasova, M. A. Kuznetsova

    This paper reports a rare case of diagnosing В-cell chronic lymphocytic leukemia (CLL) during the stage of transformation into diffuse large B-cell lymphoma (Richter syndrome). A 62-year-old patient showed a local increase in the right upper jugular lymph node confirmed by PET/CT. By immunomorphological analysis of tumor tissue from the resected lymph node, diffuse large B-cell lymphoma (CD20+, CD23+, CD5+, BCL2+, BCL6+, LEF1+, Cyclin D1–, Ki-67 70 %) was diagnosed. At the same time, the peripheral blood test and myelogram revealed an increased absolute lymphocyte count and morphological heterogeneity of lymphocytes with predominating same-type small and medium-sized cells with rounded nuclei as well as abnormal larger cells with irregular-shaped nuclei and basophilic vacuolated cytoplasm. By flow cytometry, the immunophenotype of tumor В-lymphocytes corresponded to СD5-positive mature В-cell lymphoid tumor, mostly to В-CLL. According to the analysis of the bone marrow core biopsy sample, morphological pattern and immunophenotype of tumor cells (CD79+, CD5+/–, CD23+, LEF1+, Ki-67 5 %) were consistent with the diagnosis of В-cell small lymphocytic lymphoma/В-CLL. So, based on the total of obtained data, patient was diagnosed with small lymphocytic lymphoma/В-CLL transformation into diffuse large B-cell lymphoma (Richter syndrome) with a lesion in the right upper jugular lymph node.

  • Open Access

    Bone Marrow Lymphocyte Subpopulation in Chronic Lymphocytic Leukemia Patients with Different Responses to Chemotherapy

    by Olesya Nikolaevna Selyutina, E. Yu. Zlatnik, Н. К. Гуськова, I. A. Novikova, I. B. Lysenko, A. B. Sagakyants, T. F. Pushkareva, L. Yu. Vladimirova

    AIM. To analyze the bone marrow lymphocyte subpopulation based on targeted assessment of PD-1, PD-L1, and LAG-3 marker expression in chronic lymphocytic leukemia (CLL) patients with different responses to chemotherapy. MATERIALS & METHODS. In 33 CLL patients, PD-1, PD-L1, and LAG-3 antigen expression on В-, Т-, and NK-cells of the bone marrow (BM) was analyzed by flow cytofluorometry prior to treatment and after 6 cycles of chemotherapy with rituximab. Patients were aged 58–68 years (median 64 years); there were 14 women and 19 men. Hematologic response was assessed by measurements of minimal residual disease (MRD). On this basis, patients were divided into two groups: group 1 (n = 20) with satisfactory hematologic response (MRD < 1 %) and group 2 (n = 13) with unsatisfactory hematologic response (MRD ≥ 1 %). RESULTS. Prior to treatment, the count of PD-1-, LAG-3-, CD38-, and ZAP-70-expressing BM tumor B-cells was lower in patients of group 1 than in those of group 2. After treatment, their decrease was more pronounced in group 1. Prior to treatment, patients in group 1 had a higher count of BM T-lymphocytes with CD3+, CD4+, CD8+, CD8+/CD28+, CD8+/CD28–, and CD8+/CD38+ phenotype including PD-1- but neither PD-L1- nor LAG-3-expressing T-cells. After treatment, increased T-cells with CD3+, CD4+, CD8+, Treg, CD8+/CD28+, and CD8+/CD28– phenotype including PD-1+ T-lymphocytes were detected in both groups but more pronounced in group 2. In this group, CD3+ и CD4+ T-lymphocytes maintained LAG-3 expression. Prior to treatment, all patients showed decreased NK-cells in BM. After treatment, group 1 showed a higher count of NK-cells with CD3–/CD16+/CD56+ and CD3–/CD16+/CD56+/PD-1+ phenotype and a lower count of NK-cells with CD3–/CD16+/CD56+/LAG-3+ phenotype. PD-L1 expression in NK-cells was not detected, whereas in Т- and В-cells it was moderate prior to treatment and was not identified after hematologic response was achieved. CONCLUSION. The values determined by the targeted assessment of PD-1 and LAG-3 expression in BM В-, Т-, and NK-cells prior to chemotherapy may well be used in clinical practice as additional prognostic factors in CLL. PD-1 and LAG-3 overexpression in Т-lymphocytes and NK-cells in CLL patients with MRD-positive status after chemotherapy can be regarded as evidence of the functional deficiency of these cells.